Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus

Shuliu Zhang, Matthew R. Vogt, Theodore Oliphant, Michael Engle, Evgeniy I. Bovshik, Michael S. Diamond, David W.C. Beasley

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Previous studies have established the therapeutic efficacy of humanized E16 (hE16) monoclonal antibody against West Nile virus in animals. Here, we assess the potential for West Nile virus strains encoding mutations in the hE16 epitope to resist passive immunotherapy and for the selection of neutralization escape variants during hE16 treatment. Resistance to hE16 in vivo was less common than expected, because several mutations that affected neutralization in vitro did not significantly affect protection in mice. Moreover, the emergence of resistant variants after infection with fully sensitive virus occurred but was relatively rare, even in highly immunocompromised B and T cell-deficient RAG mice.

Original languageEnglish (US)
Pages (from-to)202-205
Number of pages4
JournalJournal of Infectious Diseases
Volume200
Issue number2
DOIs
StatePublished - Jul 15 2009

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus'. Together they form a unique fingerprint.

  • Cite this